An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications

RH Weisbart, M Stempniak, S Harris, DJ Zack… - Journal of …, 1998 - Elsevier
RH Weisbart, M Stempniak, S Harris, DJ Zack, K Ferreri
Journal of autoimmunity, 1998Elsevier
A murine monoclonal anti-dsDNA antibody was found to penetrate living cells and localize
in the nucleus without pathologic effects. A single mutation in VHmarkedly enhanced cellular
penetration. The mutant antibody was produced as recombinant Fab and single chain
antibody fragments to investigate its use as a delivery system to target the cell nucleus.
Complexes were made containing Fab fragments and alkaline phosphatase conjugated
goat antibodies to mouse| gk chains. Fab fragments transported 305kDa goat antibody …
A murine monoclonal anti-dsDNA antibody was found to penetrate living cells and localize in the nucleus without pathologic effects. A single mutation in VHmarkedly enhanced cellular penetration. The mutant antibody was produced as recombinant Fab and single chain antibody fragments to investigate its use as a delivery system to target the cell nucleus. Complexes were made containing Fab fragments and alkaline phosphatase conjugated goat antibodies to mouse |gk chains. Fab fragments transported 305kDa goat antibody–enzyme complexes into the nucleus in COS-7 and CHO cells. A single chain antibody cDNA was constructed by splice overlap extension PCR and expressed in COS-7 cells. Binding of the single chain antibody to dsDNA was shown by ELISA, and cellular penetration and nuclear localization were demonstrated in COS-7 and CHO cells. The single chain antibody cDNA was ligated into the expression vector, pEGFP, to produce a fusion protein with green fluorescent protein. The fusion protein penetrated COS-7 cells and localized in the cell nucleus. The single chain antibody produced during sustained expression in CHO cells re-entered antibody-producing cells and localized in the nucleus without affecting cell viability. Our results demonstrate the potential use of a modified autoantibody as a delivery system to target the cell nucleus.
Elsevier